Please login to the form below
Epogen
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Epogen was produced by Amgen.
AZ preps new roxadustat filings, though data foxes investors
Epoetin alfa is sold by Amgen as Epogen and Janssen as Procrit, but these brands were joined by Pfizer’s lower-cost biosimilar Retacrit last year.
China first market to approve AZ’s kidney drug roxadustat
as Amgen’s Epogen (epoetin alfa) and Aranesp (darbepoetin alfa).
Pfizer gets FDA panel recommendation for biosimilar EPO
Product could be the first direct competitor to Epogen and Procrit in the US. ... If the FDA follows its panel's advice – which it generally does – Pfizer will have a direct competitor to Amgen's Epogen and Johnson &Johnson Procrit blockbuster brands
Novartis gets FDA panel backing for biosimilar Enbrel
The company has several other biosimilars in clinical development, including copycat versions of Humira, Roche's MabThera/Rituxan (rituximab), Amgen's Epogen (epoetin alfa) and Neulasta (pegfilgrastim) and Johnson &Johnson's
Amgen biosimilar matches AbbVie's Humira in psoriasis trial
to its own drugs such as Neupogen (filgrastim) and Epogen (epoetin alfa) in Europe. .
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- Novartis to test canakinumab for COVID-19, as IL-6 trial disappoints
- AZ secures capacity for one billion coronavirus vaccine doses
- UK clears NHS use of Gilead’s remdesivir for COVID-19 patients
- NICE approves Roche’s Tecentriq in TNBC after revising deal
- Courageous Conversations ep.8: 10 Tips to Create Company Culture in a Virtual World
- Impetus Digital Fireside Chat with Eddie Power from Pfizer
- Impetus Digital Fireside Chat with Deloitte Europe: The Future of Learning
- Working with, Advocating for, and Empowering Patients
- The concordance conundrum: the value of improving patient experience
- Porterhouse welcomes additional expertise to its creative team
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Working with, Advocating for, and Empowering Patients
- A holistic view of how to work with patients virtually...
- The concordance conundrum: the value of improving patient experience
- This is the first in a series of articles where we explore how the current climate presents companies with a multitude of opportunities to improve communication between healthcare organisations and...
- WHITE PAPER 05: Improving the effectiveness of clinical trial recruitment materials
- With exclusive research conducted by COUCH Health, gain insight into clinical trial recruitment materials best practice....
Quick links
Infographics
